Ipilimumab Approved in Europe for Pediatric Melanoma

January 22, 2018 – Ipilimumab has been approved by the European Commission for the treatment of patients aged 12 and older with unresectable or metastatic melanoma. The expanded indication for ipilimumab is based on data across 2 trials in which objective responses were observed in 2 of 17 patients aged ≥12 years with advanced melanoma. The responses included 1 partial response that lasted for more than 16 months. The European Medicines Agency’s … (leggi tutto)